Results 71 to 80 of about 313,244 (194)

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

open access: yesMedicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca   +6 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, Volume 13, Issue 35, 24 June 2026.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion

open access: yes, 2021
Human epidermal growth factor receptor 2 (HER-2) is overexpressed in many malignant tumors. The anti-HER2 antibody trastuzumab has been approved for treating HER2-positive early and metastatic breast cancers.
김종재   +7 more
core   +2 more sources

Optimization of the Expression of DT386-BR2 Fusion Protein in Escherichia coli using Response Surface Methodology

open access: yesAdvanced Biomedical Research, 2017
Background: The aim of this study was to determine the best condition for the production of DT386-BR2 fusion protein, an immunotoxin consisting of catalytic and translocation domains of diphtheria toxin fused to BR2, a cancer specific cell penetrating ...
Fatemeh Shafiee   +2 more
doaj   +1 more source

Delivering Proteins and Enzymes to Solid Tumors Through the Development of Stimuli‐Responsive Nanocarriers

open access: yesChemNanoMat, Volume 12, Issue 6, June 2026.
Stimuli‐responsive strategies to achieve controlled release of protein‐based therapeutic agents into solid tumors. Proteins, enzymes, and peptides have long been recognized as valuable therapeutic agents, particularly in oncology. However, their complex chemical structures render them more sensitive than smaller chemotherapeutic drugs.
Guillermo Plaza‐Palomo   +3 more
wiley   +1 more source

Mouse CD25-specific recombinant immunotoxin

open access: yes
We generated a mouse CD25 (mCD25)-specific recombinant immunotoxin termed anti-mCD25-PE38. Variable regions of a rabbit monoclonal antibody that specifically reacts to mCD25, but not to hCD25, were used to produce anti-mCD25-PE38.
Kobayashi, Kazuto
core   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 18, 15 May 2026.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez   +4 more
wiley   +1 more source

Engineered Elastin‐Like Polypeptides: Intelligent Self‐Assembling Platforms for Biomedical Application

open access: yesSmall Structures, Volume 7, Issue 3, March 2026.
Armed with unique structural and functional properties, elastin‐like polypeptides attract their attentions as programmable materials in biomedical applications, including fusion tags for protein and nucleic acid purification; nanocarriers for protein, chemotherapeutics, and imaging agent delivery; hydrogels for tissue regeneration, 3D model ...
Yang Yuan   +9 more
wiley   +1 more source

Supplementary Figure 1 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

open access: yes, 2013
PDF file - 1308K, Production and analysis of the SD1-based recombinant immunotoxin.
Yen Phung (156427)   +9 more
core   +1 more source

Two Simple Methods for Optimizing the Production of "Difficult-to-Express" GnRH-DFF40 Chimeric Protein [PDF]

open access: yesAdvanced Pharmaceutical Bulletin, 2019
Purpose: GnRH-DFF40 (gonadotropin releasing hormone - DNA fragmentation factor 40) is a humanized recombinant immunotoxin and serves as a prospective candidate for targeted therapy of gonadotropin releasing hormone receptor (GnRHR) overexpressing ...
Mahdi Barazesh   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy